Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals, Inc.    ALXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/13/2017 02/14/2017 02/15/2017 02/16/2017 02/17/2017 Date
127.77(c) 129.5(c) 132(c) 130.39(c) 128.82(c) Last
3 021 091 3 321 846 2 610 582 5 186 463 3 047 065 Volume
+1.00% +1.35% +1.93% -1.22% -1.20% Change
More quotes
Financials ($)
Sales 2017 3 489 M
EBIT 2017 1 436 M
Net income 2017 762 M
Debt 2017 911 M
Yield 2017 -
Sales 2018 4 096 M
EBIT 2018 1 800 M
Net income 2018 1 036 M
Debt 2018 779 M
Yield 2018 -
P/E ratio 2017 37,72
P/E ratio 2018 28,15
EV / Sales2017 8,53x
EV / Sales2018 7,23x
Capitalization 28 847 M
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products.Its products include soliris, strensiq and kanuma.The company... 
Sector
Pharmaceuticals
Calendar
04/27Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS, I
02/16 ALEXION PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
02/16 ALEXION PHARMACEUTICALS : Pharma's revenue forecast allays investor fears
02/16DJALEXION PHARMACEUTICALS : Revenue Rises as Sales of New Drugs Ramp Up
02/16 ALEXION PHARMACEUTICALS INC : Results of Operations and Financial Condition, Fin..
02/16 ALEXION PHARMACEUTICALS : tops 4Q profit forecasts
02/16 ALEXION PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2016 Results and ..
02/09 ALEXION PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2016 Results on..
02/06 S&P 500 ANALYST MOVES : Alxn
02/06 ALEXION PHARMACEUTICALS : Technical Reports on Biotech Stocks -- Amgen, Array Bi..
01/26 ALEXION PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2016 Results on..
More news
Sector news : Biopharmaceuticals
02/17DJSHIRE : Files 8K - Other Events
02/17 European shares retreat after week of gains; Allianz rallies after update
02/17 ASTRAZENECA : Top AstraZeneca shareholder Woodford adds to stake, bullish on out..
02/17DJROCHE : U.S. Obtains Records in Lobbyist Probe -- WSJ
02/17DJASTRAZENECA : Trial For Breast Cancer Treatment Shows Positive Results
More sector news : Biopharmaceuticals
Latest Tweets
02/18Shelton Capital Management Maintains Stake in Alexion Pharmaceuticals, Inc. $.. 
02/18Baker Bros 13F Top Holdings: $SGEN $INCY $ALXN $ACAD Top Buys: $INCY $SGEN $A..
14
02/18Takeover Candidate Alexion Is on the Mend
1
02/17$ALXN Suffers Another Blow In The UK  
02/17Alexion Pharmaceuticals's hold rating reiterated at Oppenheimer Holdings, Inc.. 
More tweets
Qtime:141
News from SeekingAlpha
02/16 Alexion Pharmaceuticals (ALXN) Q4 2016 Results - Earnings Call Transcript
02/16 Alexion Pharmaceuticals, Inc. 2016 Q4 - Results - Earnings Call Slides
02/16 Alexion Pharma revenues up 19%; non-GAAP EPS up 21% in Q4; updates 2017 guida..
02/16 Alexion Pharmaceuticals beats by $0.01, misses on revenue
02/15 Notable earnings before Thursday?s open
Advertisement
Chart ALEXION PHARMACEUTICALS, I
Duration : Period :
Alexion Pharmaceuticals, I Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Full-screen chart
Technical analysis trends ALEXION PHARMACEU...
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 163 $
Spread / Average Target 27%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David Richard Brennan Chief Executive Officer & Director
Leonard Bell Chairman
Julie O'Neill Executive Vice President-Global Operations
David John Anderson Chief Financial Officer & Executive Vice President
Martin MacKay Executive VP, Global Head-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICAL..5.29%28 847
BIOGEN INC10.56%62 397
CSL LIMITED19.78%42 143
BIOMARIN PHARMACEUTICA..8.49%15 457
GRIFOLS SA11.81%14 075
3SBIO INC2.89%2 548
More Results